These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
371 related articles for article (PubMed ID: 19637312)
1. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Balmanno K; Chell SD; Gillings AS; Hayat S; Cook SJ Int J Cancer; 2009 Nov; 125(10):2332-41. PubMed ID: 19637312 [TBL] [Abstract][Full Text] [Related]
2. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ Sci Signal; 2011 Mar; 4(166):ra17. PubMed ID: 21447798 [TBL] [Abstract][Full Text] [Related]
3. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556 [TBL] [Abstract][Full Text] [Related]
4. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation. Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021 [TBL] [Abstract][Full Text] [Related]
5. A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook. Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ Sci Signal; 2011; 4(170):er2. PubMed ID: 21674991 [TBL] [Abstract][Full Text] [Related]
6. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481 [TBL] [Abstract][Full Text] [Related]
7. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033 [TBL] [Abstract][Full Text] [Related]
8. Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling. Little AS; Balmanno K; Sale MJ; Smith PD; Cook SJ Biochem Soc Trans; 2012 Feb; 40(1):73-8. PubMed ID: 22260668 [TBL] [Abstract][Full Text] [Related]
9. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. E J; Xing J; Gong H; He J; Zhang W Tumour Biol; 2015 Feb; 36(2):1091-7. PubMed ID: 25326806 [TBL] [Abstract][Full Text] [Related]
10. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Tentler JJ; Nallapareddy S; Tan AC; Spreafico A; Pitts TM; Morelli MP; Selby HM; Kachaeva MI; Flanigan SA; Kulikowski GN; Leong S; Arcaroli JJ; Messersmith WA; Eckhardt SG Mol Cancer Ther; 2010 Dec; 9(12):3351-62. PubMed ID: 20923857 [TBL] [Abstract][Full Text] [Related]
11. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Nakayama N; Nakayama K; Yeasmin S; Ishibashi M; Katagiri A; Iida K; Fukumoto M; Miyazaki K Br J Cancer; 2008 Dec; 99(12):2020-8. PubMed ID: 19018267 [TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727 [TBL] [Abstract][Full Text] [Related]
13. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178 [TBL] [Abstract][Full Text] [Related]
15. Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. Wickenden JA; Jin H; Johnson M; Gillings AS; Newson C; Austin M; Chell SD; Balmanno K; Pritchard CA; Cook SJ Oncogene; 2008 Dec; 27(57):7150-61. PubMed ID: 18806830 [TBL] [Abstract][Full Text] [Related]
16. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. Adjei AA; Cohen RB; Franklin W; Morris C; Wilson D; Molina JR; Hanson LJ; Gore L; Chow L; Leong S; Maloney L; Gordon G; Simmons H; Marlow A; Litwiler K; Brown S; Poch G; Kane K; Haney J; Eckhardt SG J Clin Oncol; 2008 May; 26(13):2139-46. PubMed ID: 18390968 [TBL] [Abstract][Full Text] [Related]
17. Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation. Lochhead PA; Clark J; Wang LZ; Gilmour L; Squires M; Gilley R; Foxton C; Newell DR; Wedge SR; Cook SJ Cell Cycle; 2016; 15(4):506-18. PubMed ID: 26959608 [TBL] [Abstract][Full Text] [Related]
18. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784 [TBL] [Abstract][Full Text] [Related]
19. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells]. Liu Y; Chen X; Luo Z Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280 [TBL] [Abstract][Full Text] [Related]
20. The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. Sale MJ; Cook SJ Biochem J; 2013 Mar; 450(2):285-94. PubMed ID: 23234544 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]